{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:44:14Z","timestamp":1792511054666,"version":"4.5.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"33","license":[{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Cardiovascular Research Center"},{"DOI":"10.13039\/501100005035","name":"Biotronik","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005035","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>In patients with acute coronary syndrome (ACS), dual antiplatelet therapy (DAPT) with aspirin and a potent P2Y12 inhibitor is recommended for 12 months after drug-eluting stent (DES) implantation. Monotherapy with a potent P2Y12 inhibitor after short-term DAPT is an attractive option to better balance the risks of ischaemia and bleeding. Therefore, this study evaluated the efficacy and safety of ticagrelor monotherapy after short-term DAPT, especially in patients with ACS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Electronic databases were searched from inception to 11 November 2023, and for the primary analysis, individual patient data were pooled from the relevant randomized clinical trials comparing ticagrelor monotherapy after short-term (\u22643 months) DAPT with ticagrelor-based 12-month DAPT, exclusively in ACS patients undergoing DES implantation. The co-primary endpoints were ischaemic endpoint (composite of all-cause death, myocardial infarction, or stroke) and bleeding endpoint [Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding] at 1 year.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Individual patient data from two randomized clinical trials including 5906 ACS patients were analysed. At 1 year, the primary ischaemic endpoint did not differ between the ticagrelor monotherapy and ticagrelor-based DAPT groups [1.9% vs. 2.5%; adjusted hazard ratio (HR) 0.79; 95% confidence interval (CI) 0.56\u20131.13; P = .194]. The incidence of the primary bleeding endpoint was lower in the ticagrelor monotherapy group (2.4% vs. 4.5%; adjusted HR 0.54; 95% CI 0.40\u20130.72; P &amp;lt; .001). The results were consistent in a secondary aggregate data meta-analysis including the ACS subgroup of additional randomized clinical trials which enrolled patients with ACS as well as chronic coronary syndrome.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In ACS patients undergoing DES implantation, ticagrelor monotherapy after short-term DAPT was associated with less major bleeding without a concomitant increase in ischaemic events compared with ticagrelor-based 12-month DAPT.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Study registration<\/jats:title>\n                  <jats:p>PROSPERO (ID: CRD42023476470).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehae249","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T03:50:45Z","timestamp":1715831445000},"page":"3045-3056","source":"Crossref","is-referenced-by-count":14,"title":["Ticagrelor monotherapy for acute coronary syndrome: an individual patient data meta-analysis of TICO and T-PASS trials"],"prefix":"10.1093","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4526-6120","authenticated-orcid":false,"given":"Yong-Joon","family":"Lee","sequence":"first","affiliation":[{"name":"Severance Hospital, Yonsei University College of Medicine , 50-1 Yonsei-ro, Seodaemun-gu, 03722 Seoul , Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanghoon","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ewha Womans University College of Medicine Seoul Hospital , Seoul , Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Woo","family":"Kwon","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inha University Hospital , Incheon , Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsung","family":"Suh","sequence":"additional","affiliation":[{"name":"Myongji Hospital, Hanyang University College of Medicine , 55 Hwasu-ro 14 beon-gil, Deokyang-gu, 10475 Goyang , Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4911-8854","authenticated-orcid":false,"given":"Kyeong Ho","family":"Yun","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Wonkwang University Hospital , Iksan , Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Soo","family":"Kang","sequence":"additional","affiliation":[{"name":"Dankook University Hospital, Dankook University College of Medicine , Cheonan , Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6206-1704","authenticated-orcid":false,"given":"Jun-Won","family":"Lee","sequence":"additional","affiliation":[{"name":"Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine , Wonju , Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deok-Kyu","family":"Cho","sequence":"additional","affiliation":[{"name":"Yongin Severance Hospital, Yonsei University College of Medicine , Yongin , Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Kwan","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Cardiology, National Health Insurance Service Ilsan Hospital , Goyang , Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jang-Whan","family":"Bae","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Chungbuk National University College of Medicine , Cheongju , Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woong Cheol","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Gachon University Gil Medical Center , Incheon , Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seunghwan","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inje University Haeundae Paik Hospital , Busan , Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Jun","family":"Lee","sequence":"additional","affiliation":[{"name":"Severance Hospital, Yonsei University College of Medicine , 50-1 Yonsei-ro, Seodaemun-gu, 03722 Seoul , Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Jin","family":"Hong","sequence":"additional","affiliation":[{"name":"Severance Hospital, Yonsei University College of Medicine , 50-1 Yonsei-ro, Seodaemun-gu, 03722 Seoul , Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul-Min","family":"Ahn","sequence":"additional","affiliation":[{"name":"Severance Hospital, Yonsei University College of Medicine , 50-1 Yonsei-ro, Seodaemun-gu, 03722 Seoul , Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2263-3274","authenticated-orcid":false,"given":"Jung-Sun","family":"Kim","sequence":"additional","affiliation":[{"name":"Severance Hospital, Yonsei University College of Medicine , 50-1 Yonsei-ro, Seodaemun-gu, 03722 Seoul , Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byeong-Keuk","family":"Kim","sequence":"additional","affiliation":[{"name":"Severance Hospital, Yonsei University College of Medicine , 50-1 Yonsei-ro, Seodaemun-gu, 03722 Seoul , Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Guk","family":"Ko","sequence":"additional","affiliation":[{"name":"Severance Hospital, Yonsei University College of Medicine , 50-1 Yonsei-ro, Seodaemun-gu, 03722 Seoul , Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghoon","family":"Choi","sequence":"additional","affiliation":[{"name":"Severance Hospital, Yonsei University College of Medicine , 50-1 Yonsei-ro, Seodaemun-gu, 03722 Seoul , Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangsoo","family":"Jang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, CHA University College of Medicine , Seongnam , Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2090-2031","authenticated-orcid":false,"given":"Myeong-Ki","family":"Hong","sequence":"additional","affiliation":[{"name":"Severance Hospital, Yonsei University College of Medicine , 50-1 Yonsei-ro, Seodaemun-gu, 03722 Seoul , Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"key":"2024083123514814600_ehae249-B1","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"2024083123514814600_ehae249-B2","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jacc.2021.09.006","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Lawton","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2024083123514814600_ehae249-B3","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"2024083123514814600_ehae249-B4","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"2024083123514814600_ehae249-B5","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jacc.2015.06.1323","article-title":"Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention","volume":"66","author":"G\u00e9n\u00e9reux","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2024083123514814600_ehae249-B6","first-page":"804","article-title":"Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRACER) randomized trial","volume":"38","author":"Valgimigli","year":"2017","journal-title":"Eur Heart J"},{"key":"2024083123514814600_ehae249-B7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"2024083123514814600_ehae249-B8","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/CIRCULATIONAHA.123.064473","article-title":"Defining strategies of modulation of antiplatelet therapy in patients with coronary artery disease: a consensus document from the academic research consortium","volume":"147","author":"Capodanno","year":"2023","journal-title":"Circulation"},{"key":"2024083123514814600_ehae249-B9","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","article-title":"Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"key":"2024083123514814600_ehae249-B10","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N Engl J Med"},{"key":"2024083123514814600_ehae249-B11","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial","volume":"323","author":"Kim","year":"2020","journal-title":"JAMA"},{"key":"2024083123514814600_ehae249-B12","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1161\/CIRCULATIONAHA.123.066943","article-title":"Stopping aspirin within 1 month after stenting for ticagrelor monotherapy in acute coronary syndrome: the T-PASS randomized noninferiority trial","volume":"149","author":"Hong","year":"2024","journal-title":"Circulation"},{"key":"2024083123514814600_ehae249-B13","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial","volume":"321","author":"Hahn","year":"2019","journal-title":"JAMA"},{"key":"2024083123514814600_ehae249-B14","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"key":"2024083123514814600_ehae249-B15","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1161\/CIRCULATIONAHA.120.046251","article-title":"The safety and efficacy of aspirin discontinuation on a background of a P2Y12 inhibitor in patients after percutaneous coronary intervention: a systematic review and meta-analysis","volume":"142","author":"O'Donoghue","year":"2020","journal-title":"Circulation"},{"key":"2024083123514814600_ehae249-B16","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/eurheartj\/ehaa739","article-title":"Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials","volume":"42","author":"Giacoppo","year":"2021","journal-title":"Eur Heart J"},{"key":"2024083123514814600_ehae249-B17","doi-asserted-by":"crossref","first-page":"n1332","DOI":"10.1136\/bmj.n1332","article-title":"P2y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials","volume":"373","author":"Valgimigli","year":"2021","journal-title":"BMJ"},{"key":"2024083123514814600_ehae249-B18","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1001\/jama.2015.3656","article-title":"Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD statement","volume":"313","author":"Stewart","year":"2015","journal-title":"JAMA"},{"key":"2024083123514814600_ehae249-B19","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1093\/eurheartj\/ehaa670","article-title":"Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS","volume":"41","author":"Baber","year":"2020","journal-title":"Eur Heart J"},{"key":"2024083123514814600_ehae249-B20","doi-asserted-by":"crossref","first-page":"e015560","DOI":"10.1161\/JAHA.119.015560","article-title":"Efficacy and safety of ticagrelor monotherapy by clinical presentation: pre-specified analysis of the GLOBAL LEADERS trial","volume":"10","author":"Vranckx","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2024083123514814600_ehae249-B21","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2024083123514814600_ehae249-B22","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"2024083123514814600_ehae249-B23","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/s41569-022-00725-6","article-title":"P2y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention","volume":"19","author":"Capodanno","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"2024083123514814600_ehae249-B24","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1001\/jama.2021.0716","article-title":"Oral antiplatelet therapy after acute coronary syndrome: a review","volume":"325","author":"Kamran","year":"2021","journal-title":"JAMA"},{"key":"2024083123514814600_ehae249-B25","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0140-6736(18)30493-8","article-title":"6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial","volume":"391","author":"Hahn","year":"2018","journal-title":"Lancet"},{"key":"2024083123514814600_ehae249-B26","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/jamacardio.2021.5244","article-title":"Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: the STOPDAPT-2 ACS randomized clinical trial","volume":"7","author":"Watanabe","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2024083123514814600_ehae249-B27","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jacc.2019.11.056","article-title":"Ticagrelor with or without aspirin after PCI: the TWILIGHT platelet substudy","volume":"75","author":"Baber","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2024083123514814600_ehae249-B28","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/jamacardio.2019.3355","article-title":"Benefit and risks of aspirin in addition to ticagrelor in acute coronary syndromes: a post hoc analysis of the randomized GLOBAL LEADERS trial","volume":"4","author":"Tomaniak","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2024083123514814600_ehae249-B29","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jcin.2020.11.036","article-title":"Ticagrelor monotherapy versus ticagrelor with aspirin in patients with ST-segment elevation myocardial infarction","volume":"14","author":"Lee","year":"2021","journal-title":"J Am Coll Cardiol Intv"},{"key":"2024083123514814600_ehae249-B30","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/ehjacc\/zuab033","article-title":"Ticagrelor alone vs. dual antiplatelet therapy from 1 month after drug-eluting coronary stenting among patients with STEMI': a post hoc analysis of the randomized GLOBAL LEADERS trial","volume":"10","author":"Gamal","year":"2021","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2024083123514814600_ehae249-B31","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/j.jacc.2019.08.1038","article-title":"Ticagrelor alone versus dual antiplatelet therapy from 1 month after drug-eluting coronary stenting","volume":"74","author":"Franzone","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2024083123514814600_ehae249-B32","doi-asserted-by":"crossref","first-page":"627","DOI":"10.4244\/EIJ-D-20-00145","article-title":"Ticagrelor alone or conventional dual antiplatelet therapy in patients with stable or acute coronary syndromes","volume":"16","author":"Franzone","year":"2020","journal-title":"EuroIntervention"},{"key":"2024083123514814600_ehae249-B33","first-page":"574","article-title":"Safety and efficacy of ticagrelor monotherapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention: an individual patient data meta-analysis of TWILIGHT and TICO randomized trials","volume":"149","author":"Baber","year":"2024","journal-title":"Circulation"},{"key":"2024083123514814600_ehae249-B34","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4244\/EIJ-D-22-00886","article-title":"Single antiplatelet therapy directly after percutaneous coronary intervention in non-ST-segment elevation acute coronary syndrome patients: the OPTICA study","volume":"19","author":"van der Sangen","year":"2023","journal-title":"EuroIntervention"},{"key":"2024083123514814600_ehae249-B35","doi-asserted-by":"crossref","DOI":"10.1093\/ehjopen\/oead075","article-title":"One-year follow-up of patients treated with single antiplatelet therapy directly after percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome","volume":"3","author":"van der Sangen","year":"2023","journal-title":"Eur Heart J Open"},{"key":"2024083123514814600_ehae249-B36","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1253\/circj.CJ-23-0051","article-title":"Prasugrel monotherapy after percutaneous coronary intervention with biodegradable-polymer platinum-chromium everolimus eluting stent for Japanese patients with chronic coronary syndrome (ASET-JAPAN)","volume":"87","author":"Muramatsu","year":"2023","journal-title":"Circ J"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/45\/33\/3045\/58968739\/ehae249.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/45\/33\/3045\/58968739\/ehae249.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:04:31Z","timestamp":1725149071000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/45\/33\/3045\/7674940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":36,"journal-issue":{"issue":"33","published-online":{"date-parts":[[2024,5,16]]},"published-print":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehae249","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9,1]]},"published":{"date-parts":[[2024,5,16]]}}}